Kushlinskiĭ N E, Bassalyk L S, Svetozarskiĭ N L, Matveev B P, Gorilovskiĭ L M, Makarova G V, Bukharkin B V, Shakhov E V, Kliuchikhin O Z
Urol Nefrol (Mosk). 1993 Jan-Feb(1):7-10.
The role of androgen receptors (ARs) registration in cytosol tumor fraction has been investigated in 86 new cases of prostatic cancer. The frequency of occurrence and mean ARs levels in the tumor were found dependent on the disease stage and tumor differentiation. Well-differentiated against moderately and poorly differentiated prostatic cancers contain ARs in 73% and 39% of cases, respectively, in concentrations 10-100 fmol/mg protein and 100 fmol/mg protein, respectively. Patients with well-differentiated prostatic cancer at stage T1-4N0M0 and 10-100 fmol/mg protein ARs in the tumor tend to achieve longer remissions compared to patients with ARs-free tumors or tumor comprising ARs in concentrations surpassing 100 fmol/mg protein. No significant correlation exists between remission duration in patients on radiation treatment combined with estrogen therapy and the presence, levels of ARs in the tumor.
对86例前列腺癌新病例研究了雄激素受体（ARs）在细胞溶质肿瘤组分中的表达情况。发现肿瘤中ARs的出现频率和平均水平取决于疾病分期和肿瘤分化程度。高分化前列腺癌与中低分化前列腺癌相比，ARs阳性率分别为73%和39%，浓度分别为10 - 100飞摩尔/毫克蛋白和100飞摩尔/毫克蛋白。T1 - 4N0M0期高分化前列腺癌且肿瘤中ARs为10 - 100飞摩尔/毫克蛋白的患者，与无ARs肿瘤或ARs浓度超过100飞摩尔/毫克蛋白的肿瘤患者相比，往往缓解期更长。接受放射治疗联合雌激素治疗的患者，缓解期持续时间与肿瘤中ARs的存在及水平之间无显著相关性。
